Mainz, Germany – Researchers at the Institute of Molecular Biology (IMB) and Johannes Gutenberg University Mainz (JGU) have further uncovered the secrets of telomeres, the caps that protect the ends of our chromosomes. They discovered that an RNA molecule called TERRA helps to ensure that very short (or broken) telomeres get fixed again. The work, which was recently published in the journal Cell, provides new insights into cellular processes that regulate cell senescence and survival in ageing and cancer.
Telomeres protect the ends of our chromosomes, much like the plastic cap at the end of a shoelace that prevents the lace from unravelling. Over a cell’s lifetime, telomeres get gradually shorter with each cell division and therefore the protective cap becomes less and less effective. If they get too short, it is a signal for the cell that its genetic material is compromised and the cell stops dividing. Telomere shortening and reduced cell division are considered a hallmark of ageing and likely contribute to the ageing process. However, telomere shortening is also a defence mechanism against cancer because highly proliferative cells can only divide when their telomeres do not shorten. Therefore, telomere shortening is a double-edged sword and has to be carefully regulated to strike a balance between ageing and cancer prevention. When a telomere accidentally gets cut short early in a cell’s lifetime, it needs to be fixed so that the cell doesn’t become senescent too early.
“In the life of a cell, you have to find some sort of balance between cancer prevention and ageing. Telomeres are at the nexus between the two, so understanding how they are maintained is really important”, said Brian Luke, Professor at the JGU Institute for Developmental Biology and Neurobiology and Adjunct Director at IMB.
Luke and his lab were interested in understanding how the cell recognises these shortened and damaged telomeres that have lost their caps. Furthermore, they wanted to determine which factors were important for promoting the repair of short telomeres. This information could help in understanding why cells either commit to senescence or continue to grow.
In their recent paper, published in the prestigious journal Cell, Luke and his group have shown that one of the keys to understanding this problem is TERRA. TERRA is an RNA species that accumulates specifically at the ends of critically short telomeres by binding directly to the DNA and signals to the cell that these telomeres should be repaired, allowing the cell to carry on dividing.
“We already knew that short telomeres play a key role in determining the onset of cellular senescence, but we didn’t really understand which features of short telomeres were important. What we have found with TERRA is an intricate regulatory system that explains how short telomeres are identified by the cell”, said Luke.
The paper is actually the result of two different research projects on telomeres in the Luke lab. Diego Bonetti was looking into the regulation of TERRA in the cell cycle, and found that TERRA levels were different at different stages of the cell cycle. Meanwhile, Arianna Lockhart and Marco Graf were investigating the accumulation of TERRA at short telomeres. When they discovered that the pattern of cyclic TERRA accumulation was different between short and long telomeres, they knew they were on to something and joined forces for this project.
Their joint work led them to realise that TERRA actually accumulates at all telomeres, but at long telomeres it is rapidly removed with the help of proteins Rat1 and RNase H2. These proteins bind preferentially to the long telomeres and ensure that TERRA is removed, but they are not present at the critically short telomeres, which means that TERRA remains for a longer time. This mechanism ensures the subsequent repair of the short telomere, which is crucial for the cell to survive and keep dividing.
Luke’s work was carried out in yeast; however, telomeres and TERRA are found across all organisms with linear chromosomes. The researchers expect their work to be applicable to humans as well. Their next step will be to look into these processes in human cells and interrogate their implications for ageing and cancer.
Graf M*, Bonetti D*, Lockhart A*, Serhal K, Kellner V, Maicher A, Jolivet P, Teixeira MT and Luke B (2017). Telomere length determines TERRA and R-1 loop regulation through the cell cycle. Cell, doi: http://dx.doi.org/10.1016/j.cell.2017.06.006
Brian Luke is an Adjunct Director at IMB and a Heisenberg Professor at Johannes Gutenberg University Mainz. Further information about research in Brian Luke’s lab can be found at www.imb.de/luke.
About the Institute of Molecular Biology gGmbH
The Institute of Molecular Biology gGmbH (IMB) is a centre of excellence in the life sciences that was established in 2011 on the campus of Johannes Gutenberg University Mainz (JGU). Research at IMB concentrates on three cutting-edge areas: epigenetics, developmental biology, and genome stability. The Boehringer Ingelheim Foundation has dedicated 100 million euros for a period of ten years to cover the operating costs for research at IMB, while the state of Rhineland-Palatinate provided approximately 50 million euros for the construction of a state-of-the-art building.
For more information about IMB, please visit: www.imb.de.
About Johannes Gutenberg University Mainz
Johannes Gutenberg University Mainz (JGU) is a globally renowned research university with about 32,500 students. With its PRISMA Cluster of Excellence and the MAINZ Graduate School of Excellence, JGU has successfully demonstrated its research capacity in the latest German Excellence Initiative. Thanks to its outstanding researchers and the establishment of vibrant research networks specifically in the fields of particle and hadron physics, materials sciences, the life sciences as well as translational medicine, Mainz University is in the international top league of research and maintains close ties with regional, national, and international partners in the scientific, cultural, and business sectors.
For more information about Mainz University, please visit: www.uni-mainz.de/eng
About the Boehringer Ingelheim Foundation
The Boehringer Ingelheim Foundation is an independent, non-profit organisation committed to the promotion of the medical, biological, chemical and pharmaceutical sciences. It was established in 1977 by Hubertus Liebrecht (1931-1991), a member of the shareholder family of the company Boehringer Ingelheim. With the PLUS 3 Perspectives Programme and the Exploration Grants, the foundation supports independent group leaders. It also endows the internationally renowned Heinrich Wieland Prize as well as awards for up-and-coming scientists. In addition, the foundation pledged to donate 100 million euros to finance the scientific running of the IMB at Johannes Gutenberg University Mainz for ten years. In 2013, the Boehringer Ingelheim Foundation donated a further 50 million euros to Johannes Gutenberg University Mainz.
For more information about the Foundation, please visit: www.boehringer-ingelheim-stiftung.de.